

5 WHAT IS CLAIMED IS:

1. A conjugate exhibiting interferon  $\beta$  activity, which conjugate comprises at least one first non-polypeptide moiety covalently attached to an interferon  $\beta$  polypeptide variant, which interferon  $\beta$  polypeptide variant differs from a wild-type human interferon  $\beta$  by at least one introduction and at least one removal of an amino acid residue, which amino acid residue  
10 comprises an attachment group for the first non-polypeptide moiety.

2. The conjugate of claim 1, wherein the first non-polypeptide moiety is selected from the group consisting of: a polymer molecule, a lipophilic compound, a sugar moiety and an organic derivatizing agent.

3. The conjugate of claim 2, wherein the polymer molecule comprises linear or  
15 branched polyethylene glycol.

4. The conjugate of claim 1, wherein the first non-polypeptide moiety comprises a polymer molecule having an attachment group selected from the group consisting of: lysine, aspartic acid, glutamic acid and cysteine.

5. The conjugate of claim 4, wherein the first non-polypeptide moiety is a  
20 polymer molecule having lysine as an attachment group.

6. A conjugate exhibiting interferon  $\beta$  activity, which conjugate comprises at least one first non-polypeptide moiety conjugated to at least one lysine residue of an interferon  $\beta$  polypeptide variant, which interferon  $\beta$  polypeptide variant differs from a wild-type human interferon  $\beta$  by at least one introduction or removal of a lysine residue.

7. The conjugate of claim 6, which interferon  $\beta$  polypeptide variant differs  
25 from a wild-type human interferon  $\beta$  by introduction and removal of a lysine residue.

8. The conjugate of claim 6, wherein the lysine residue removed is selected from one or more residue selected from the group consisting of: K19, K33, K45, K52, K99, K105, K108, K115, K123, K134 and K136.

5 9. The conjugate of claim 8, wherein the lysine residue has been substituted with an arginine or a glutamine residue.

10. The conjugate of claim 6, wherein the interferon  $\beta$  polypeptide variant comprises one of the following sets of mutations:

10 K19R+K45R+K123R;  
K19Q+K45R+K123R;  
K19R+K45Q+K123R;  
K19R+K45R+K123Q;  
K19Q+K45Q+K123R;  
K19R+K45Q+K123Q;  
15 K19Q+K45R+K123Q;  
K19Q+K45Q+K123Q;  
K45R+K123R;  
K45Q+K123R;  
K45Q+K123Q;  
20 K45R+K123Q;  
K19R+K123R;  
K19Q+K123R;  
K19R+K123Q;  
K19Q+K123Q;  
25 K19R+K45R;  
K19Q+K45R;  
K19R+K45Q;  
K19Q+K45Q;  
K52R+K134R;  
30 K99R+K136R;  
K33R+K105R+K136R;  
K52R+K108R+K134R;  
K99R+K115R+K136R;  
K19R+K33R+K45R+K123R;  
35 K19R+K45R+K52R+K123R;  
K19R+K33R+K45R+K52R+K123R; or  
K19R+K45R+K52R+K99R+K123R.

11. The conjugate of claim 6, wherein a lysine residue has been introduced in a position selected from the group consisting of: N4, F8, L9, R11, S12, F15, Q16, Q18, L20, W22,  
40 Q23, G26, R27, L28, E29, Y30, L32, R35, M36, N37, D39, P41, E42, E43, L47, Q48, Q49, T58,  
Q64, N65, F67, A68, R71, Q72, D73, S75, S76, G78, N80, E81, I83, E85, N86, A89, N90, Y92,  
H93, H97, T100, L102, E103, L106, E107, E109, D110, F111, R113, G114, L116, M117, L120,  
H121, R124, G127, R128, L130, H131, E137, Y138, H140, I145, R147, V148, E149, R152,  
Y155, F156, N158, R159, G162, Y163, R165 and N166 of SEQ ID NO 2.

5           12. The conjugate of claim 11, wherein the interferon  $\beta$  polypeptide variant comprises at least one substitution selected from the group consisting of: N4K, R11K, G26K, R27K, Q48K, Q49K, R71K, D73K, S75K, E85K, A89K, Y92K, H93K, F111K, R113K, L116K, R124K, G127K and Y155K.

10           13. The conjugate of claim 12, wherein the substitution is selected from the group consisting of: Q49K and F111K.

14. The conjugate of claim 6, comprising at least two introduced lysine residues.

15           15. The conjugate of claim 11, wherein the interferon  $\beta$  polypeptide variant further comprises the removal of at least one lysine residue.

16. The conjugate of claim 15, wherein the at least one lysine residue is selected from the group consisting of: K19, K33, K45, K52, K99, K105, K108, K115, K123, K134 and K136.

17. The conjugate of claim 15, comprising one of the following sets of mutations:

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

K19R+K45R+F111K+K123R;  
K19R+K45R+Q49K+F111K+K123R;  
K19R+K45R+Q49K+K123R;  
K19R+K45R+ F111K;  
K19R+K45R+Q49K+F111K;  
K19R+Q49K+K123R;  
K19R+Q49K+F111K+K123R;  
K45Q+F111K+K123Q;  
K45R+Q49K+K123R; or  
K45R+Q49K+F111K+K123R.

18. The conjugate of claim 1 or 6, wherein the non-polypeptide moiety comprises a polymer selected from the group consisting of: SS-PEG, NPC-PEG, aldehyd-PEG, mPEG-SPA, PEG-SCM and mPEG-BTC.

19. A conjugate exhibiting interferon  $\beta$  activity, which conjugate comprises at least one first non-polypeptide moiety conjugated to at least one cysteine residue of an interferon  $\beta$  polypeptide variant, which interferon  $\beta$  polypeptide variant differs from a wild type interferon

5  $\beta$  polypeptide by the introduction of at least one cysteine residue at a position selected from the group consisting of: F8, L9, R11, S12, F15, Q16, Q18, L20, W22, L28, L32, M36, P41, T58, Q64, N65, F67, I83, E85, N86, A89, N90, Y92, H93, H97, T100, L102, E103, L106, M117, L120, H121, R124, G127, R128, L130, H131, H140, I145, R147, V148, E149, R152, Y155, and F156 of SEQ ID NO 2.

10 20. The conjugate of claim 19, wherein the interferon  $\beta$  polypeptide variant further comprises removal of at least one cysteine residue.

21. The conjugate of claim 20, wherein the cysteine residue removed comprises C17.

15 22. The conjugate of claim 19, wherein the interferon  $\beta$  polypeptide variant comprises at least one of the mutations C17S or N80C.

23. The conjugate of claim 19, wherein the interferon  $\beta$  polypeptide variant comprises the mutations C17S and N80C.

24. The conjugate of claim 19, wherein the first non-polypeptide moiety is a polymer molecule.

20 25. A conjugate exhibiting interferon  $\beta$  activity, which conjugate comprises at least one first non-polypeptide moiety having an acid group as an attachment group, which moiety is conjugated to at least one aspartic acid or glutamic acid residue of an interferon  $\beta$  polypeptide variant, which interferon  $\beta$  polypeptide variant differs from a wild-type human interferon  $\beta$  by at least one introduction or removal of an aspartic acid or a glutamic acid residue.

25 26. The conjugate of claim 25, wherein at least one amino acid residue selected from the group consisting of: N4, L5, L6, F8, L9, Q10, R11, S12, S13, F15, Q16, Q18, K19, L20, W22, Q23, L24, N25, G26, R27, Y30, M36, Q46, Q48, Q49, I66, F67, A68, I69, F70, R71, S75, T82, I83, L87, A89, N90, V91, Y92, H93, Q94, I95, N96, H97, K108, F111, L116, L120, K123, R124, Y126, G127, R128, L130, H131, Y132, K134, A135, H140, T144, R147, Y155, 30 F156, N158, R159, G162, Y163 and R165 of SEQ ID NO 2 is substituted with an aspartic acid residue or a glutamic acid residue.

5           27. The conjugate of claim 25, comprising introduction of at least two introduced aspartic acid or glutamic acid residues.

          28. The conjugate of claim 25, comprising at least two first non-polypeptide moieties.

10           29. The conjugate of claim 25, wherein the first non-polypeptide moiety is a polymer molecule.

          30. The conjugate of claim 29, wherein the second non-polypeptide moiety comprises a sugar moiety.

15           31. The conjugate of claim 34, wherein the amino acid sequence of the interferon  $\beta$  polypeptide variant further comprises at least one of an introduction or a removal of an *in vivo* glycosylation site.

          32. The conjugate of claim 31, wherein the first non-polypeptide moiety is a polymer molecule having lysine as an attachment group.

          33. The conjugate of claim 1, 6, 19 or 25, which conjugate comprises a second non-polypeptide moiety.

20           34. The conjugate of claim 33, wherein the polypeptide comprises at least one removed amino acid residue comprising an attachment group for the first non-polypeptide moiety, and at least one introduced amino acid residue comprising an attachment group for the second non-polypeptide moiety.

25           35. The conjugate of claim 33, wherein the amino acid sequence of the interferon  $\beta$  polypeptide variant comprises at least two removed amino acid residues comprising attachment groups for the first non-polypeptide moiety and at least one introduced amino acid residue comprising an attachment group for the second non-polypeptide moiety.

          36. The conjugate of claim 33, wherein the second non-polypeptide moiety comprises a sugar moiety.

5 37. A conjugate exhibiting interferon  $\beta$  activity, which conjugate comprises at least one polymer molecule and at least one sugar moiety covalently attached to an interferon  $\beta$  polypeptide variant, which interferon  $\beta$  polypeptide variant differs from a wild-type human interferon  $\beta$  by

(a) at least one introduction or removal of an amino acid residue, which amino  
10 acid residue comprises an attachment group for the polymer molecule, and

(b) at least one introduction or removal of an amino acid residue, which amino acid residue comprises an attachment group for the sugar moiety,

with the proviso that when the attachment group for the polymer molecule is a cysteine residue, and the sugar moiety is an N-linked sugar moiety, introduction of a cysteine  
15 residue does not destroy an N-glycosylation site.

38. The conjugate of claim 37, wherein the polymer molecule has lysine as an attachment group.

39. The conjugate of claim 38, wherein the polypeptide variant comprises at least one removed amino acid residue comprising an attachment group for the first non-  
20 polypeptide moiety and at least one introduced amino acid residue comprising an attachment group for the second non-polypeptide moiety.

40. The conjugate of claim 37, wherein the interferon  $\beta$  polypeptide variant comprises one of the following sets of mutations:

25 K19R+K45R+Q49N+Q51T+F111N+R113T+K123R;  
K19R+K45R+Q49N+Q51T+F111N+R113T; or  
K19R+K45R+Q49N+Q51T+ K123R.

41. The conjugate of claim 1, 6, 19, 25 or 37, wherein the interferon  $\beta$  polypeptide variant comprises a modified N-terminus, which modified N-terminus is unavailable for conjugation to a non-polypeptide moiety.

30 42. A conjugate exhibiting interferon  $\beta$  activity, which conjugate comprises an interferon  $\beta$  polypeptide variant, which interferon  $\beta$  polypeptide variant differs from a wild-type human interferon  $\beta$  by introduction of at least one glycosylation site, the conjugate further comprising at least one un-PEGylated sugar moiety attached to the introduced glycosylation site.

5 43. A conjugate exhibiting interferon  $\beta$  activity, which conjugate comprises an  
interferon  $\beta$  polypeptide variant, which interferon  $\beta$  polypeptide variant differs from a wild-type  
human interferon  $\beta$  by at least one introduction or removal of a glycosylation site by introducing  
or removing one or more amino acid residues comprising a glycosylation site in a position that is  
occupied by an amino acid residue having at least 25% of its side chain surface exposed in  
10 wildtype human interferon  $\beta$ .

44. The conjugate of claim 42 or 43, wherein the interferon  $\beta$  polypeptide  
variant comprises at least one mutation selected from the group consisting of: S2N+N4T,  
L9N+R11T, R11N, S12N+N14T, F15N+C16S, Q16N+Q18T, K19N+L21T, Q23N+H25T,  
G26N+L28T, R27N+E29T, L28N+Y30T, D39T, K45N+L47T, Q46N+Q48T, Q48N+F50T,  
15 Q49N+Q51T, Q51N+E53T, R71N+D73T, Q72N, D73N, S75N, S76N+G78T, L88T, Y92T,  
N93N+I95T, L98T, E103N+K105T, E104N+L106T, E107N+E109T, K108N+D110T, D110N,  
F111N+R113T and L116N.

45. The conjugate of claim 44, wherein the interferon  $\beta$  polypeptide comprises  
one of the following sets of substitutions: Q49N+Q51T; Q49N+Q51T+F111N+R113T; or  
20 Q49N+Q51T+R71N+D73T+F111N+R113T.

46. The conjugate of claim 42 or 43, wherein the amino acid sequence further  
differs by removal of an amino acid comprising a glycosylation site.

47. The conjugate of claim 46, wherein the glycosylation site comprises an N-  
glycosylation site.

25 48. A conjugate exhibiting interferon  $\beta$  activity, which conjugate comprises a  
sugar moiety covalently attached to an interferon  $\beta$  polypeptide variant, which interferon  $\beta$   
polypeptide variant differs from a wild-type human interferon  $\beta$  by removal of at least one  
glycosylation site.

49. The conjugate of claim 43 or 48, wherein an N-glycosylation site is removed  
30 by the mutation N80C.



5           **50.** The conjugate of claim 1, 6, 19, 25, 37 or 43, wherein the interferon  $\beta$  polypeptide further comprises at least one substitution in a position selected from among M1, C17, N80 or V101.

**51.** The conjugate of claim 50, wherein the interferon  $\beta$  polypeptide variant comprises at least one substitution selected from M1del, M1K or C17S.

10           **52.** A nucleotide sequence encoding an interferon  $\beta$  polypeptide variant, which interferon  $\beta$  polypeptide variant comprises component of a conjugate exhibiting interferon  $\beta$  activity.

**53.** A host cell comprising the nucleotide sequence of claim 52.

**54.** An expression vector comprising the nucleotide sequence of claim 52.

15           **55.** A host cell comprising the expression vector of claim 54.

**56.** The host cell of claim 53 or 55, which host cell comprises a CHO cell, a BHK cell, a HEK293 cell or an SF9 cell.

**57.** A method of reducing immunogenicity or increasing functional *in vivo* half-life or serum half-life of an interferon  $\beta$  polypeptide variant, the method comprising:

20           (a) introducing an amino acid residue comprising an attachment group for a first non-polypeptide moiety into a position exposed at the surface of an interferon  $\beta$  polypeptide that does not contain such group; or

          (b) removing an amino acid residue comprising an attachment group for the first non-polypeptide moiety; and

25           conjugating the interferon  $\beta$  polypeptide variant with the first non-polypeptide moiety.

**58.** The method of claim 57, wherein the non-polypeptide moiety is selected from the group consisting of a polymer molecule, a sugar moiety, a lipophilic group and an organic derivatizing agent.



5           **59.** A method for preparing a conjugate exhibiting interferon  $\beta$  activity, the method comprising:

          contacting an interferon  $\beta$  polypeptide variant with a first non-polypeptide moiety under conditions conducive for conjugation; and

          recovering the conjugate exhibiting interferon  $\beta$  activity.

10           **60.** A pharmaceutical composition comprising a conjugate exhibiting interferon  $\beta$  activity and a pharmaceutically acceptable diluent, carrier, excipient or adjuvant.

**61.** The pharmaceutical composition of claim 60, wherein the pharmaceutical composition is effective for the treatment of one or more diseases.

15           **62.** The pharmaceutical composition of claim 61, wherein the pharmaceutical composition is effective for the treatment of multiple sclerosis.

**63.** A method for treating a mammal with multiple sclerosis comprising administering an effective amount of the pharmaceutical composition of claim 60.

20           **64.** A method for treating a mammal having circulating antibodies against interferon  $\beta$  1a and/or 1b, which method comprises administering an effective amount of the pharmaceutical composition of claim 60.

**65.** The method of claim 63 or 64, wherein the mammal is a human.

**66.** A cell culture comprising

          a) a host cell transformed with a nucleotide sequence encoding an interferon  $\beta$  polypeptide variant; and,

25           b) a culture medium.

**67.** The cell culture of claim 66, wherein the culture medium comprises an interferon  $\beta$  polypeptide variant produced by expressing the nucleotide sequence.

**68.** The cell culture of claim 67, wherein the concentration of the interferon  $\beta$  polypeptide variant is at least 800,000 IU/ml of medium.

005280" 59584960

5            69. The cell culture of claim 67, wherein the concentration of the interferon  $\beta$  polypeptide variant is in the range of 800,000-3,500,000 IU/ml medium.

70. A cell culture comprising a host cell of claim 53 or 55.

71. A method of producing an interferon  $\beta$  polypeptide variant, the method comprising:

10            (a) culturing a cell expressing an interferon  $\beta$  polypeptide variant in a culture medium, such that the concentration of the interferon  $\beta$  polypeptide variant in the medium is at least 800,000 IU/ml medium; and

(b) recovering the interferon  $\beta$  polypeptide variant.

15            72. The method of claim 71, wherein the concentration of the interferon  $\beta$  polypeptide variant is between 800,000 and 3,000,000 IU/ml medium.

Add  
A2